Tags

Type your tag names separated by a space and hit enter

Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort.
Cancer Epidemiol Biomarkers Prev. 2008 Mar; 17(3):655-60.CE

Abstract

BACKGROUND

Studies of postmenopausal hormone therapy and lung cancer incidence have reported positive, negative, and null associations. Most of these studies, however, have had limited ability to control rigorously for cigarette smoking or to examine risk separately by smoking status.

METHODS

We examined the association between postmenopausal hormone therapy and lung cancer incidence by smoking status among 72,772 women in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate rate ratios (RR).

RESULTS

During follow-up from 1992 to 2003, we identified 659 cases of incident lung cancer. Current use of any postmenopausal hormone therapy was significantly associated with decreased risk of incident lung cancer [multivariate RR, 0.76; 95% confidence interval (95% CI), 0.62-0.92]. Similar risk estimates were observed for unopposed estrogen use (RR, 0.76; 95% CI, 0.60-0.94) and for estrogen plus progestin (RR, 0.76; 95% CI, 0.57-1.01). Risk associated with current use of postmenopausal hormone therapy was decreased among never smokers (RR, 0.56; 95% CI, 0.33-0.95) as well as current smokers (RR, 0.76; 95% CI, 0.55-1.05) and former smokers (RR, 0.76; 95% CI, 0.58-0.99). Former hormone use was not associated with lung cancer. No trend with duration of hormone use was detected.

CONCLUSION

These results support the hypothesis that postmenopausal hormone therapy is associated with reduced risk of lung cancer, although the absence of a dose-response relationship weakens the evidence for causality.

Authors+Show Affiliations

Epidemiology and Surveillance Research, American Cancer Society, National Home Office, 250 Williams Street Northwest, Atlanta, GA 30303, USA. crodrigu@cancer.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18349283

Citation

Rodriguez, Carmen, et al. "Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort." Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, vol. 17, no. 3, 2008, pp. 655-60.
Rodriguez C, Spencer Feigelson H, Deka A, et al. Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(3):655-60.
Rodriguez, C., Spencer Feigelson, H., Deka, A., Patel, A. V., Jacobs, E. J., Thun, M. J., & Calle, E. E. (2008). Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored By the American Society of Preventive Oncology, 17(3), 655-60. https://doi.org/10.1158/1055-9965.EPI-07-2683
Rodriguez C, et al. Postmenopausal Hormone Therapy and Lung Cancer Risk in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2008;17(3):655-60. PubMed PMID: 18349283.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Postmenopausal hormone therapy and lung cancer risk in the cancer prevention study II nutrition cohort. AU - Rodriguez,Carmen, AU - Spencer Feigelson,Heather, AU - Deka,Anusila, AU - Patel,Alpa V, AU - Jacobs,Eric J, AU - Thun,Michael J, AU - Calle,Eugenia E, PY - 2008/3/20/pubmed PY - 2008/6/18/medline PY - 2008/3/20/entrez SP - 655 EP - 60 JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology JO - Cancer Epidemiol. Biomarkers Prev. VL - 17 IS - 3 N2 - BACKGROUND: Studies of postmenopausal hormone therapy and lung cancer incidence have reported positive, negative, and null associations. Most of these studies, however, have had limited ability to control rigorously for cigarette smoking or to examine risk separately by smoking status. METHODS: We examined the association between postmenopausal hormone therapy and lung cancer incidence by smoking status among 72,772 women in the Cancer Prevention Study II Nutrition Cohort. Proportional hazards modeling was used to calculate rate ratios (RR). RESULTS: During follow-up from 1992 to 2003, we identified 659 cases of incident lung cancer. Current use of any postmenopausal hormone therapy was significantly associated with decreased risk of incident lung cancer [multivariate RR, 0.76; 95% confidence interval (95% CI), 0.62-0.92]. Similar risk estimates were observed for unopposed estrogen use (RR, 0.76; 95% CI, 0.60-0.94) and for estrogen plus progestin (RR, 0.76; 95% CI, 0.57-1.01). Risk associated with current use of postmenopausal hormone therapy was decreased among never smokers (RR, 0.56; 95% CI, 0.33-0.95) as well as current smokers (RR, 0.76; 95% CI, 0.55-1.05) and former smokers (RR, 0.76; 95% CI, 0.58-0.99). Former hormone use was not associated with lung cancer. No trend with duration of hormone use was detected. CONCLUSION: These results support the hypothesis that postmenopausal hormone therapy is associated with reduced risk of lung cancer, although the absence of a dose-response relationship weakens the evidence for causality. SN - 1055-9965 UR - https://www.unboundmedicine.com/medline/citation/18349283/Postmenopausal_hormone_therapy_and_lung_cancer_risk_in_the_cancer_prevention_study_II_nutrition_cohort_ L2 - http://cebp.aacrjournals.org/cgi/pmidlookup?view=long&pmid=18349283 DB - PRIME DP - Unbound Medicine ER -